Skip to main content

Table 1 Dose levels

From: A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Dose level (DL)Durvalumab (IV)Olaparib tablet (oral)Cediranib (oral)
DL − 11500 mg every 4 weeks200 mg twice daily15 mg once daily
(5 days on/2 days off)
DL 1 (starting dose)1500 mg every 4 weeks300 mg twice daily15 mg once daily
(5 days on/2 days off)
DL 21500 mg every 4 weeks300 mg twice daily20 mg once daily
(5 days on/2 days off)